- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: CpG.
Displaying page 1 of 1.
EudraCT Number: 2004-003813-18 | Sponsor Protocol Number: C016 | Start Date*: 2004-12-16 |
Sponsor Name:Pfizer Inc | ||
Full Title: A continuation study of CPG 7909 Injection in patients with matastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy | ||
Medical condition: Patients with metastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004686-15 | Sponsor Protocol Number: LUD 03-007 | Start Date*: 2005-08-04 |
Sponsor Name:Ludwig Institute For Cancer Research | ||
Full Title: Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma ... | ||
Medical condition: HLA-A2 patients with metastatic melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004684-30 | Sponsor Protocol Number: LICR No.: LUD 02-001 | Start Date*: 2005-08-04 |
Sponsor Name:Ludwig Institute for Cancer Research | ||
Full Title: Phase I/II Studie zur Immunisierung mit dem Peptid MAGE-3.A1 gemischt mit der immunologischen Adjuvans CpG 7909 bei Patienten mit metastasiertem Melanom | ||
Medical condition: Phase I/II Studie zur Immunisierung mit dem MAGE-3.A1 Peptid gemischt mit der immunologischen Adjuvans CpG 7909 für Patienten mit metastastasiertem Melanom | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005389-11 | Sponsor Protocol Number: VAC035 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria | |||||||||||||
Medical condition: Plasmodium falciparum malaria | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002818-13 | Sponsor Protocol Number: DEALSZ-2021-001 | Start Date*: 2023-05-12 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin Berlin | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit... | |||||||||||||
Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004007-64 | Sponsor Protocol Number: 111476 | Start Date*: 2009-07-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma | ||
Medical condition: First-line treatment for patients with unresectable, MAGE-A3-positive stage III or stage IVa melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) IE (Completed) FR (Completed) ES (Completed) IT (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001060-38 | Sponsor Protocol Number: DECO | Start Date*: 2013-05-28 |
Sponsor Name:Academic Medical center | ||
Full Title: Pre-operative Decitabine in colon cancer: a proof of principal study | ||
Medical condition: colon cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001159-20 | Sponsor Protocol Number: STH14404 | Start Date*: 2008-09-25 | ||||||||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic... | ||||||||||||||||||
Medical condition: Chronic cyclical pelvic pain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000035-23 | Sponsor Protocol Number: VLA2001-307 | Start Date*: 2022-04-11 | |||||||||||
Sponsor Name:Valneva Austria GmbH | |||||||||||||
Full Title: OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCI... | |||||||||||||
Medical condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002324-41 | Sponsor Protocol Number: PH2/051 | Start Date*: 2006-11-30 | |||||||||||
Sponsor Name:Cancer Research UK | |||||||||||||
Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat... | |||||||||||||
Medical condition: Progressive, advanced ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004555-35 | Sponsor Protocol Number: A8501001 | Start Date*: 2005-12-15 |
Sponsor Name:Pfizer Inc | ||
Full Title: International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell l... | ||
Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004557-10 | Sponsor Protocol Number: A8501002 | Start Date*: 2006-02-21 |
Sponsor Name:Pfizer Inc | ||
Full Title: International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lun... | ||
Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) SK (Completed) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001138-40 | Sponsor Protocol Number: IOM-605 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:iOMEDICO AG | |||||||||||||
Full Title: First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma | |||||||||||||
Medical condition: Locally advanced or metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016636-13 | Sponsor Protocol Number: 113173 | Start Date*: 2010-06-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients... | |||||||||||||
Medical condition: First-line treatment of patients with PRAME-positive unresectable stage III or IV metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001588-52 | Sponsor Protocol Number: A8501004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Pfizer Pharma GmbH | |||||||||||||
Full Title: A randomized phase II trial of pemetrexed with or without PF-3512676 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of one prior chemothe... | |||||||||||||
Medical condition: Treatment of patients with locally advanced or metastatic non-small lung cancer (NSLC) after failure of one prior chemotherapy regimen for advanced disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.